

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/AJPS

Erratum

Correction to “Folic acid-conjugated liposomal vincristine for multidrug resistant cancer therapy”



Chenyu Wang^{a,1}, Linglin Feng^{c,1}, Xiangkun Yang^{a,1}, Fei Wang^a, Weiyue Lu^{a,b,*}

^a Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education & PLA, Shanghai 201203, China

^b State Key Laboratory of Molecular Engineering of Polymers (Fudan University), Shanghai 200433, China

^c Shanghai Institute of Planned Parenthood Research, Key Laboratory of Contraceptives and Devices Research, NPFC of China, Shanghai 200032, China

ARTICLE INFO

Article history:

Available online 14 July 2022

In the original version of this article on p 122, two inappropriate images were placed in B and C of Fig. 1, which didn't represent the group of FA-PEG-LS and PEG-LS/VCR. In the revised graphic provided below, the appropriate images are used. These corrections do not change the results and conclusions of this work.




Fig. 1 – TEM images of PEG-LS (A), FA-PEG-LS (B), PEG-LS/VCR (C) and FA-PEG-LS/VCR (D).

DOI of original article: [10.1016/j.ajps.2013.07.015](https://doi.org/10.1016/j.ajps.2013.07.015)

* Correspondence author.

¹ Wang CY, Feng LL, Yang XK, et al. Folic acid-conjugated liposomal vincristine for multidrug resistant cancer therapy. Asian Journal of Pharmaceutical Sciences 2013;8:118–127. DOI: [10.1016/j.ajps.2013.07.015](https://doi.org/10.1016/j.ajps.2013.07.015)

Peer review under responsibility of Shenyang Pharmaceutical University.

<https://doi.org/10.1016/j.ajps.2022.07.001>

1818-0876/© 2022 Published by Elsevier B.V. on behalf of Shenyang Pharmaceutical University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

On P126, three inappropriate images were placed in B1, B2, and D2 of Fig. 9, which didn't represent the group of PEG-LS/VCR (HE and TUNEL) and Normal Saline (TUNEL). In the revised graphic provided below, the appropriate images are used. These corrections do not change the results and conclusions of this work.




Fig. 9 – Tumor tissue sections of TUNEL assay. Significant difference analysis of AI by histogram. From left to right, Group II, III, IV and V were showed respectively ($P < 0.01$, vs FA-PEG-LS/VCR; A – Group II, B – Group III, C – Group IV, D – Group V; 1-HE, 2-TUNEL).